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Abstract. The phosphorylation of pyruvate dehydrogenase 
(PDH) by pyruvate dehydrogenase kinase (PDK) 4 inhibits 
its ability to induce a glycolytic shift. PDK4 expression is 
upregulated in various types of human cancer. Because PDK4 
regulation is critical for metabolic changes in cancer cells, 
it is an attractive target for cancer therapy given its ability 
to shift glucose metabolism. It was previously shown that a 
novel PDK4 inhibitor, cryptotanshinone (CPT), suppressed 
the three‑dimensional (3D)‑spheroid formation of pancreatic 
and colorectal cancer cells. In the present study, the effects 
of CPT on the invasiveness of bladder cancer cells were 
investigated. CPT significantly suppressed the invasiveness 
and 3D‑spheroid formation of T24 and J82 bladder cancer 
cells. CPT also suppressed the phosphorylation of PDH and 
β‑catenin, as well as the expression of N‑cadherin, which 
are all critical for inducing epithelial‑mesenchymal transi‑
tion (EMT). The knockdown of β‑catenin or PDK4 using 
specific small interfering RNAs suppressed N‑cadherin 
expression and invasiveness in T24 cells. An mTOR inhibitor 
also suppressed the phosphorylation of β‑catenin and 
N‑cadherin expression. Furthermore, CPT injection signifi‑
cantly suppressed pancreatic tumor growth and peritoneal 
dissemination of highly metastatic SUIT‑2 pancreatic cancer 
cells in a mouse orthotopic pancreatic cancer model, without 
evident toxicity. Moreover, immunohistochemistry analyses 
demonstrated decreased β‑catenin expression in CPT‑treated 
pancreatic tumors compared with control tumors. Taken 
together, these results indicate that CPT reduced the invasive‑
ness and metastasis of bladder cancer cells by suppressing 
EMT via the mTOR/β‑catenin/N‑cadherin pathway.
Introduction
Under aerobic conditions, the majority of proliferating cancer 
cells preferentially metabolize glucose via glycolysis, which is 
a primary metabolic hallmark of cancer cells (1‑3). Pyruvate 
dehydrogenase kinases (PDKs) are key molecules in the mito‑
chondria, which via decarboxylation, regulate the oxidative 
metabolism of pyruvate into acetyl‑CoA. The physiological role 
of the PDK family is to phosphorylate the pyruvate dehydroge‑
nase (PDH) complex (4). The inhibition of PDKs can restimulate 
the mitochondria metabolism of pyruvate in cancer cells (5), 
which subsequently inhibits tumor growth (6). Studies have 
revealed that the expression of PDK4, one of four PDK isoforms 
(PDK1‑4), is frequently upregulated in various cancer types; 
thus, its regulation is critical for metabolic changes in cancer 
cells (7,8). Trinidad et al (9) reported that PDK4‑knockdown 
using specific small interfering (si)RNAs suppressed lung 
and colorectal cancer cell proliferation, which suggests that 
PDK4 is an attractive target for cancer therapy. Despite reports 
demonstrating the therapeutic inhibition of PDK activity by 
dichloroacetate (DCA) (10‑12), the half maximal inhibitory 
concentration necessary for PDK4 inhibition is in the range of 
57.8‑500 µM (7,13), and DCA exhibited reversible peripheral 
neuropathy in a number of clinical trials (10,14). Previous studies 
have attempted to identify novel compounds that can suppress 
PDK4 activity at sub‑micromolar concentrations (13,14). 
Our previous study demonstrated that cryptotanshinone 
(CPT), which is obtained from the traditional Chinese herb 
Salvia miltiorrhiza Bunge (danshen), effectively inhibited 
PDK4 activity at low concentrations (micromolar‑order) to 
suppress malignant phenotypes, including three‑dimensional 
(3D)‑spheroid formation, anchorage‑independent growth, 
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cellular proliferation and in vivo tumor growth of human 
pancreatic and colorectal cancer (15).
Invasiveness and metastasis are key defining characteris‑
tics of cancer cell malignancy, and metastasis is a major cause 
of cancer‑associated death (16,17). Although invasiveness and 
metastasis are considered critical targets in the development of 
new therapeutic strategies, effective reagents that target these 
processes have yet to be identified. Previously, changes in 
energy metabolism have been shown to be closely associated 
with the invasive and metastatic abilities of cancer cells (18,19). 
Changes in cancer cell metabolism increase acid production 
in the cancer cells involved (20), which leads to normal cell 
death (21), extracellular matrix degradation by proteolytic 
enzymes (22), and enhanced migration and invasion capacity. 
Therefore, targeting cancer cell metabolism may provide a 
novel approach for inhibiting cancer cell invasiveness and 
metastasis, and result in more favorable treatment outcomes.
Bladder cancer is the 10th most common cancer type 
worldwide, with ~550,000 new cases diagnosed in 2018 (23). 
Bladder cancer is a complex disease associated with high 
morbidity and mortality rates. The treatment outcomes 
of radical cystectomy for muscle invasive bladder cancer 
(MIBC) combined with chemotherapy are insufficient (24), 
and the five‑year survival rate is only ~5% in patients with 
metastatic bladder cancers (25). As there have been no 
significant improvements in the treatment outcome over the 
last three decades (26), new treatment strategies for MIBC 
and metastatic bladder cancers are necessary. PDK4 expres‑
sion has been shown to be markedly higher in high‑grade 
than in low‑grade bladder cancers without the overexpression 
of PDK1, 2 or 3 (27). Therefore, the aim of the present study 
was to identify novel compounds to treat intractable bladder 
cancer by investigating the effects of CPT on the invasive and 
metastatic capacity of human bladder cancer cells. 
Materials and methods
Cell culture. The human bladder cancer cell lines (T24 and 
J82) were cultured with RPMI‑1640 (Nacalai Tesque, Inc.) 
supplemented with 10% fetal calf serum (FCS; Sigma‑Aldrich; 
Merck KGaA), penicillin (100 U/ml; Meiji Seika Pharma, Co., 
Ltd.) and streptomycin (100 µg/ml; Meiji Seika Pharma, Co., 
Ltd.), at 37˚C (5% CO2) in a humidified atmosphere. The SUIT‑2 
human pancreatic cancer cell line was cultured in Dulbecco's 
modified Eagle's medium (DMEM, Nacalai Tesque, Inc.). 
Additionally, a nonadherent culture was created by coating the 
culture dishes with poly‑(2‑hydroxyethyl methacrylate) reagent 
(poly‑HEMA; Sigma‑Aldrich; Merck KGaA). T24 cells were 
purchased from the American Type Culture Collection in 
2000, and maintained in our laboratory. J82 and SUIT‑2 cells 
were purchased from the American Type Culture Collection 
in 2019 and the Japanese Collection of Research Bioresources 
Cell Bank (Osaka, Japan) in 2018, respectively. The T24 cell 
line was authenticated by short tandem repeat analysis in 2018, 
as previously described (28).
Reagents. CPT was purchased from Cosmo Bio Co., Ltd., and was 
dissolved in dimethyl sulfoxide (DMSO) to prepare 10‑mM stock 
solutions for the in vitro experiments. IL‑6‑hydroxymethyl‑chiro‑ 
inositol2(R)‑ 2‑ O‑methyl‑3‑O‑octadecylcarbonate (Akt inhibitor, 
Calbiochem; Merck KGaA), temsirolimus (Tokyo Chemical 
Industry Co., Ltd.) and PD98059 (Cell Signaling Technology, 
Inc.) were dissolved in DMSO to prepare the 20‑mM stock solu‑
tions for the in vitro experiments. The same volume of DMSO 
was added to the control samples in all experiments. 
3D‑spheroid formation assay. The 3D‑spheroid formation assay 
was performed using 96‑well V‑bottom plates (PrimeSurface®; 
Sumitomo Bakelite Co., Ltd.) as previously described (28). 
Briefly, 1x103 cells were seeded in triplicate into each well 
in complete culture medium. After three days of incubation 
at 37˚C (5% CO2) in a humidified atmosphere, images of 
spheroid formation were captured using phase contrast micros‑
copy (magnification, x4; Olympus Corporation). To determine 
the number of viable cells in the 3D‑spheroid, the ATP content 
was quantified using the luminescence‑based CellTiter‑Glo® 
3D cell viability assay (Promega Corporation) according to the 
manufacturer's protocol. The Caspase‑Glo® 3/7 assay (Promega 
Corporation) was used to measure caspase‑3 and ‑7 activities 
according to the manufacturer's protocol.
In vitro invasion assay. The in vitro invasive potential of cancer 
cells was determined using a Matrigel™ Basement Membrane 
Matrix Invasion Chamber (chamber size, 6.4 mm; membrane 
surface area, 0.3 cm2; pore size, 8 µm; BD Biosciences), 
according to the manufacturer's instructions (29). A total of 
500 µl cell suspension (2x104 T24 and 4x104 J82 cells/ml) was 
added to each chamber, and incubated for two or three days, 
respectively, at 37˚C in a humidified 5% CO2 atmosphere. 
Culture medium without FCS was used in upper chambers, and 
750 µl culture medium with 10% FCS was added to the lower 
chambers. Non‑invasive cells were removed from the upper 
surface of the membrane using a cotton swab. The invasive 
cells on the underside of the membrane were harvested using 
Diff‑Quik™ (Kokusai Shiyaku Co., Ltd.) and counted under a 
light microscope (magnification, x100). The duration of each 
Diff‑Quik™ staining step was 3 min at room temperature. 
Each sample was then analyzed in triplicate.
Cell cycle analysis. Cell cycle distribution was evaluated using 
the Cycletest Plus DNA Reagent kit with a FACSCalibur flow 
cytometer system and ModFit 3.2 software (both Becton, 
Dickinson and Company). Briefly, the cells were collected 
after treatment with CPT (0, 10 and 20 µM at 37˚C for 
24 h) and fixed in 70% ethanol at ‑20˚C for 18 h. The cells 
were washed twice with phosphate‑buffered saline and then 
pelleted by centrifugation at 400 x g at room temperature for 
5 min. The cell pellets were incubated with 250 µl solution 
A (trypsin in a spermine tetrahydrochloride detergent buffer) 
at room temperature for 10 min, 200 µl solution B (trypsin 
inhibitor and ribonuclease A in citrate stabilizing buffer with 
spermine tetrahydrochloride) at room temperature for 10 min, 
and then 200 µl solution C (propidium iodide and spermine 
tetrahydrochloride in citrate stabilizing buffer) in the dark 
at 4˚C for 10 min. The cells were then flow cytometrically. 
Small interfering RNA (siRNA) transfection. For the siRNA 
experiment, cells were transfected with 50 nM Silencer® 
Select PDK4 siRNA (s10262; Thermo Fisher Scientific, 
Inc.) and β‑catenin siRNA (sense; 5'‑CAG GGG GUU GUG 
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GUU AAG CUC UU‑3', antisense; 5'‑AAG AGC UUA ACC 
ACA ACC CCC UG‑3') (30) using Lipofectamine® RNAiMax 
(Invitrogen; Thermo Fisher Scientific, Inc.) for 24 h according 
to the manufacturer's protocol. A non‑specific siRNA duplex 
(GeneDesign, Inc.) served as the control. 
Western blotting. The 60‑mm culture dishes were precoated 
with poly‑HEMA at room temperature for 24 h. A total of 
5x105 cells were seeded into a poly‑HEMA‑coated dish, 
and cultured with CPT for 48 h (37˚C) under nonadherent 
culture conditions. Cell lysate preparation and western blot‑
ting were conducted as previously described (31). Amersham 
ECL western blotting detection kit (Cytiva) was used for 
visualization according to the manufacturer's protocol. 
The experiments were repeated at least three times. Mouse 
monoclonal antibodies for α‑tubulin (1:1,000; DM1A, 
cat. no. T9026) were purchased from Sigma‑Aldrich; 
Merck KGaA. Mouse monoclonal antibodies for E‑cadherin 
(1:500; 36/E, cat. no. 610181) were purchased from BD 
Biosciences. Anti‑PDH mouse monoclonal antibodies (1:500; 
cat. no. ab110330), anti‑phospho‑PDH rabbit polyclonal 
antibodies (1:500; S293; cat. no. ab92696), and anti‑PDK4 
rabbit polyclonal antibodies (1:500; cat. no. ab63157) were 
purchased from Abcam. Rabbit monoclonal antibodies for 
4E‑BP1 (1:500; 53H11, cat. no. #9644), phospho‑4E‑BP1 
(1:500; S65, 174A9, cat. no. #9456), phospho‑Akt (1:500; S473, 
D9E, cat. no. #4060), Erk1/2 (1:500; 137F5, cat. no. #4695), 
phospho‑Erk1/2 (1:500; T202/Y204, 20G11, cat. no. #4376), 
MEK1/2 (1:500; 47E6, cat. no. #9126), phospho‑MEK1/2 
(1:500; S221, 166F8, cat. no. #2338), S6K (1:500; 49D7, 
cat. no. #2708), phospho‑S6K (1:500; T421/S424, #9204), 
β‑catenin (1:500; D10A8, #8480), phospho‑β‑catenin (1:500; 
S552, D8E11, cat. no. #5651), N‑cadherin (1:500; D4R1H, 
cat. no. #13116), and caspase‑3 (1:500; 8G10, cat. no. #9665); 
rabbit polyclonal antibodies for Akt (1:500; cat. no. #9272) 
and phospho‑β‑catenin (1:500; S33/37/T41, #9561); and 
mouse monoclonal antibodies for CD44 (1:1,000; 156‑3C11, 
cat. no. #3570) and epithelial cell adhesion molecule (EpCAM) 
(1:500; VU1D9, cat. no. #2929) were purchased from Cell 
Signaling Technology, Inc. Rabbit polyclonal antibodies for 
lamin A/C (1:500; cat. no. #10298‑1‑AP) were purchased from 
ProteinTech Group, Inc. The horse radish peroxidase‑conju‑
gated anti‑mouse IgG (1:10,000, cat. no. NA931, from sheep) 
and anti‑rabbit IgG (1:10,000, cat. no. NA934, from donkey) 
secondary antibodies were purchased from Cytiva. Caspase‑3 
control cell extracts (cat. no. #9663) for the negative and posi‑
tive controls for apoptosis analysis were purchased from Cell 
Signaling Technology, Inc.
Subcellular fractionation. Cytoplasmic and nuclear protein 
fractions were extracted using NE‑PER® cytoplasmic and 
nuclear extraction regents (Pierce; Thermo Fisher Scientific, 
Inc.) according to the manufacturer's protocol. Western blot 
analysis was used to analyze the extracted protein samples. 
α‑tubulin and lamin A/C were used as cytoplasmic and nuclear 
endogenous controls, respectively. 
Laboratory animals. A total of 10 female, five‑week‑old 
BALB/c‑nu/nu nude mice (5 control and 5 CPT‑treated mice, 
weight 16‑18 g) were purchased from CLEA Japan and housed 
in a specific pathogen‑free room with controlled temperature 
(20‑22˚C) and humidity (50‑60%), and a preset light‑dark cycle 
(12:12 h). All mice were allowed ad libitum access to food (CE‑2; 
CLEA Japan, Inc.) and water. The use of animals in the experi‑
mental protocols was reviewed and approved by the Management 
Committee of the Research Center for Animal Life Science at 
Shiga University of Medical Science (Shiga, Japan).
Orthotopic pancreatic cancer model of nude mice. A total of 
10 5‑week‑old mice were anesthetized by intraperitoneal injec‑
tion of pentobarbital (50 mg/kg) and maintained by inhalation 
of 1% isoflurane. The abdominal cavity was opened using a 
1.5‑cm wide longitudinal laparotomy pointing slightly to the 
left. Then, 2x105 SUIT‑2 cells in 100 µl DMEM were injected 
into the tail of the pancreas with a 27‑gauge needle. Both the 
operation and injection were performed by the same person 
(CJK and YT, respectively). The pancreas was placed back into 
the abdominal cavity, which was then closed using interrupted 
suturing with 4‑0 Nylon, and penicillin G (200 U/20 g) was 
injected intramuscularly to prevent postoperative infection. 
After seven days, five mice were intraperitoneally administered 
40 mg/kg of CPT (suspended in 8% DMSO and 2% Solutol) 
every two days for two weeks. The control mice were admin‑
istered a vehicle (8% DMSO and 2% Solutol) every two days 
for two weeks. Finally, the mice were sacrificed by cervical 
dislocation one day after the last administration. The pancreas, 
heart, lungs, liver and kidneys were resected and fixed with 
10% buffered formalin at 4˚C for 24 h. The intestine with the 
mesentery were also resected, and the tumor nodules of the 
mesentery were counted macroscopically. The volume of the 
largest tumor nodule in one mouse was calculated using the 
following formula: 3.14xAxB2/6, where A and B represent the 
long and short diameters, respectively. A and B were measured 
using the histological preparations of hematoxylin and eosin 
staining.
Histopathological analyses. Serial 3‑µm sections of 
formalin‑fixed (10%, 4˚C for 24 h), paraffin‑embedded tissues 
were histologically evaluated by hematoxylin and eosin 
staining and light microscope. For the immunohistochemical 
analyses, dewaxed sections were assessed using β‑catenin 
antibodies via the streptavidin‑biotin‑peroxidase method 
[Histofine® MAX‑PO (MULTI); Nichirei Biosciences, Inc.], 
according to the manufacturer's instructions. 
Statistical analyses. All quantitative data are presented as the 
mean ± standard deviation. One‑way ANOVA following by 
Tukey's test for multiple comparisons, Wilcoxon's rank sum 
test, and Welch's t‑test were used for the statistical analyses. 
All analyses were performed using the R statistical software 
package, version 2.6.2 (https://www.r‑project.org/), and P<0.05 
was considered to indicate a statistically significant difference.
Results
Effects of CPT on bladder cancer cell invasiveness in vitro. 
To assess the suppressive activity of CPT on the invasive‑
ness of human bladder cancer, its effects on the 3D‑spheroid 
formation and invasiveness of two human bladder cancer cell 
lines (T24 and J82) were investigated. The effect of CPT on 
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PDK4 activity was evaluated by monitoring the phosphory‑
lation PDH, the target protein of PDK4. Under nonadherent 
culture conditions, 10‑20 µM CPT effectively suppressed PDH 
phosphorylation at serine 293, a hallmark of PDH activity (32), 
in a dose‑dependent manner (Fig. 1A). The expression levels 
of PDH and α‑tubulin (the internal control protein) remained 
unaffected by CPT treatment, while PDK4 expression was 
suppressed by 20 µM CPT. The antioncogenic effect of CPT 
was assessed by evaluating T24 and J82 cell 3D‑spheroid 
formation, a method is frequently used in cancer research to 
more closely mimic the tumor environment (33). 3D‑spheroid 
formation was morphologically altered in these cell lines by 
CPT treatment (3‑10 µM; Fig. S1). The edge of the spheroid 
became less distinct following CPT treatment. Moreover, CPT 
treatment (3‑20 µM) significantly decreased the ATP concen‑
tration in these cell lines in a dose‑dependent manner, which 
is closely associated with the number of viable cancer cells 
in the spheroids (Fig. 1B). Furthermore, the invasiveness of 
both cell lines was significantly suppressed by CPT treatment 
(Fig. 1C‑D). The induction of apoptosis was also assessed by 
monitoring the cleavage of caspase‑3. Caspase‑3 activation 
(cleaved, lower band) was not detected in T24 and J82 cells 
(Fig. 1E). Furthermore, the Caspase‑Glo® 3/7 assay was used 
to measure caspase‑3 and ‑7 activities. The number of viable 
cells in 3D‑spheroids was assessed using ATP activity in 
T24 and J82 cells. There were significantly fewer viable T24 
and J82 cells following CPT treatment (Fig. S2A). Similarly, 
the caspase‑3/7 activities decreased in these cells, and the 
caspase‑3/7/ATP activity ratio was not increased following 
CPT treatment (Fig. S2B‑C). This result was most likely due 
to the decrease in caspase‑3/7 activities reflecting the decrease 
in the viable number of T24 and J82 spheroids after CPT 
treatment. Furthermore, flow cytometry was used to assess 
the pro‑apoptotic effect of CPT. As shown in Figs. 1F and S3, 
CPT treatment increased the sub‑G1 fraction at a concentration 
of 20 µM in both cell lines. These results indicate that CPT 
suppressed invasiveness and 3D‑spheroid formation in bladder 
cancer cells, and that apoptosis may play a partial role in these 
anti‑oncogenic activities.
Alterations in invasion‑related proteins following CPT treat‑
ment. To clarify the molecular mechanisms by which CPT 
suppresses cellular invasiveness, changes in the expression 
of proteins associated with epithelial‑mesenchymal transition 
(EMT) were evaluated in T24 and J82 cells. Figs. 2A and S4 
show that CPT treatment significantly decreased N‑cadherin 
expression in a dose‑dependent manner. However, E‑cadherin 
expression was not detected in these cells. A CPT concentra‑
tion of 10‑20 µM also suppressed β‑catenin phosphorylation at 
S552 in a dose‑dependent manner. β‑catenin phosphorylation 
at S552 induces β‑catenin accumulation in the nucleus and 
increases its transcriptional activity (34). However, 10 µM CPT 
enhanced β‑catenin phosphorylation at S33/S37/T41, which 
has been shown to promote its ubiquitylation and proteasomal 
degradation (35,36). In the present study, CPT treatment 
at 20 µM suppressed both total β‑catenin expression and 
β‑catenin phosphorylation at S33/S37/T41 (Figs. 2A and S4). 
This dual function of CPT for β‑catenin phosphorylation is 
thought to be responsible for the suppression of cell invasive‑
ness via β‑catenin suppression. A subcellular fractionation 
assay was then performed to detect changes in the subcellular 
localization of β‑catenin in T24 cells (Fig. 2B). CPT treatment 
significantly suppressed the phosphorylation of β‑catenin at 
S552 and its accumulation in the nucleus. By contrast, the 
levels of β‑catenin and phosphorylated β‑catenin at S552 in 
the cytoplasm were weakly decreased by CPT, compared with 
the levels in the nucleus. The β‑catenin signaling pathway has 
been reported to play a crucial role in the EMT process via the 
nuclear translocation of β‑catenin (37). Therefore, these results 
indicate that CPT can effectively suppress the accumulation of 
β‑catenin in the nucleus.
Since 3D‑spheroid formation is considered to be a pheno‑
type of cancer stem cells (15), and because these spheroids are 
associated with invasiveness (28), alterations in the expression 
of CD44 and EpCAM, which are stem cell markers of human 
bladder cancer, were investigated in T24 and J82 cells. Changes 
in cancer‑related signaling pathway proteins, such as those of the 
MEK/Erk, Akt and mTOR cascades, were also investigated. As 
shown in Figs. 2A and S4, CPT suppressed the cancer stem cell 
phenotypes of these cells. Additionally, CPT suppressed MEK 
and Erk phosphorylation (Fig. 2C). Furthermore, CPT treat‑
ment decreased Akt phosphorylation at S473 and suppressed 
the phosphorylation of S6K (Fig. S4) and 4E‑BP1, the target 
proteins of mTOR kinase (Fig. 2C). These results indicate that 
CPT suppressed the MEK/Erk, Akt and mTOR signaling path‑
ways in these bladder cancer cell lines. 
The role of β‑catenin in the CPT‑induced suppression of 
N‑cadherin expression and cellular invasiveness. To confirm 
whether the alterations in EMT‑associated protein levels, 
growth‑associated signaling pathways, and cancer stemness 
markers induced by CPT were the result of inhibited PDK4 
activity, PDK4 expression was knocked down in T24 cells, 
which effectively suppressed the expression of PDK4 and PDH 
phosphorylation (Fig. 3A). PDK4‑knockdown significantly 
decreased ATP concentration and suppressed cellular inva‑
siveness, as well as altering the morphology of the spheroid 
(Figs. 3B and C, and S5). As shown in Fig. 3D, it also suppressed 
the phosphorylation of β‑catenin at S552, N‑cadherin expres‑
sion, the MEK/Erk, Akt and mTOR signaling pathways, 
and CD44 expression. However, PDK4‑siRNA did not alter 
β‑catenin phosphorylation at S33/S37/T41. Taken together, 
these results support the finding that the suppressive effects 
caused by CPT were the result of PDK4 inactivation. 
To clarify the roles of N‑cadherin and β‑catenin in the 
CPT‑induced suppression of invasiveness, β‑catenin was 
knocked down in T24 cells. β‑catenin‑siRNA significantly 
decreased the ATP concentration and suppressed cellular 
invasiveness, 3D‑spheroid formation, and β‑catenin expres‑
sion (Figs. 3B, C and E, and S5). Phosphorylation at S552 and 
N‑cadherin expression were also suppressed (Fig. 3E). The 
MEK/Erk, Akt and mTOR signaling pathways, as well as CD44 
expression, were not affected by the β‑catenin‑knockdown. 
These results demonstrate that the inactivation of β‑catenin 
plays a crucial role in suppressing cellular invasiveness; more‑
over, N‑cadherin acts downstream of β‑catenin to suppress the 
invasiveness induced by CPT. To assess the roles of Erk, Akt 
and mTOR in the suppression of β‑catenin and N‑cadherin, 
T24 cells were treated with inhibitors of these kinases. As 
shown in Fig. 4, the inhibitors (40 µM) acted on their target 
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kinases to suppress the mTOR targets, and the phosphoryla‑
tion of S6K and 4EBP1 (Fig. 4A), Akt (Fig. 4B) and Erk 
(Fig. 4C). Although Akt and Erk inhibitors could not suppress 
β‑catenin phosphorylation at S552 and N‑cadherin expres‑
sion, the mTOR inhibitor, temsirolimus, suppressed β‑catenin 
phosphorylation at S552 and N‑cadherin expression (Fig. 4D). 
These results indicate that the mTOR pathway acts upstream 
of β‑catenin/N‑cadherin in T24 cells. Additionally, Akt, 
mTOR, and Erk inhibitors did not suppress CD44 expression 
(Fig. 4D), indicating that the downregulation of CD44 by CPT 
occurs independently of these signaling pathways. 
Antioncogenic effects of CPT in an in vivo orthotopic pancre‑
atic cancer model of nude mice. To investigate the effects of 
CPT on in vivo metastasis, the aim was to establish a subcu‑
taneous cancer cell xenograft model of lung metastasis via 
injection of J82 cells into the tail vein, and a liver metastasis 
model via injection into the spleens of nude mice. However, J82 
metastatic tumors could not be detected in these experimental 
models. Therefore, an orthotopic pancreatic cancer model 
was created, which closely mimics pancreatic tumor forma‑
tion using the highly metastatic pancreatic cancer cell line, 
SUIT‑2 (38). The effects of CPT treatment in SUIT‑2 cells were 
similar to those in bladder cancer cells; specifically, multiple 
oncogenic signaling pathways components were suppressed, 
including the phosphorylation of PDH and β‑catenin at S552, 
and the expression of N‑cadherin and CD44 (Fig. 5A). SUIT‑2 
cells were injected into the pancreases of nude mice, and 
Figure 1. Effects of CPT on the invasiveness of human bladder cancer cells in vitro. (A) Western blot detection of PDH and PDK4 in T24 and J82 cells treated 
with CPT for 48 h. α‑tubulin was used as the internal control. (B) Effects of CPT on the viability of spheroids formed from T24 and J82 cells. Bars indicate 
the mean ± SD. Adenosine triphosphate content was assessed using CellTiter‑Glo® 3D assays. **P<0.001 compared with untreated cells using Tukey's test. 
Effects of CPT on the invasiveness of (C) T24 and (D) J82 cells. Each sample was assayed in triplicate, and the bars represent the mean ± SD. Images of T24 
cells invading the Matrigel membrane. Images were captured at x100 magnification. **P<0.001 compared with untreated cells using Tukey's test. (E) Western 
blot analysis of caspase‑3 cleavage in T24 and J82 cells treated with CPT. Untreated (‑) or cytC‑treated Jurkat cell extracts (caspase‑3 control cell extracts, 
Cell Signaling Technology, Inc.) were used as negative or positive controls, respectively. α‑tubulin was used as the internal control. (F) Apoptotic cytotoxicity 
of CPT in T24 and J82 cells. Stacked bars indicate the cell cycle profiles after treatment with CPT for 24 h; the sub‑G1 fraction, presented as the black area 
on the top of each bar, indicates the proportion of the apoptotic cells. CPT, cryptotanshinone; PDH, pyruvate dehydrogenase; PDK4, pyruvate dehydrogenase 
kinase 4; p‑, phosphorylated; cytC, cytochrome C.
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after one week, CPT was repeatedly administered (40 mg/kg, 
intraperitoneally) every two days for two weeks. At day 1 
post‑injection, SUIT‑2 cells formed a pancreatic cancer‑like 
tumor and disseminated nodules of the mesentery. Pancreatic 
tumor formation was moderately suppressed by CPT treat‑
ment in the pancreatic orthotopic cancer model (Fig. 5B‑D). 
The volume of the largest tumor nodule in one mouse was 
0.011±0.008 and 0.061±0.028 ml in CPT‑treated and control 
groups, respectively. CPT treatment significantly decreased 
tumor growth in the pancreatic orthotopic cancer model 
(P=0.005). Furthermore, histopathological analyses revealed 
that tumor morphology in the CPT‑treated mice was similar 
to that in the control mice. However, β‑catenin was diffusely 
expressed in the cytoplasm of pancreatic cancer cells, while 
this was observed at the cytoplasmic membrane in normal 
pancreatic cells (Fig. 5E). β‑catenin expression was markedly 
suppressed in the CPT‑treated pancreatic tumors compared 
with the control tumors (Fig. 5F), and there were significantly 
fewer tumor nodules in the mesenterium after CPT treatment 
compared with the control tumors (Fig. 5G‑I). Although histo‑
pathological examinations of the heart, lungs, liver and kidneys 
were also performed, no side effects from CPT treatment were 
observed under these experimental conditions. These results 
indicate that CPT suppressed in vivo tumor growth and peri‑
toneal dissemination in an orthotopic pancreatic cancer model 
of nude mice.
Discussion
In the present study, CPT, a novel PDK4 inhibitor, was shown 
to suppress the invasiveness of bladder cancer cells in vitro. 
Furthermore, CPT inhibited in vivo tumor growth and 
peritoneal dissemination in an orthotopic pancreatic cancer 
model of nude mice. Although multiple molecular changes 
were observed in human bladder cancer cells following CPT 
treatment, including those of the β‑catenin/N‑cadherin, 
Erk, Akt and mTOR signaling pathways, as well as cancer 
stemness, siRNA‑knockdown experiments highlighted the 
critical role of the β‑catenin/N‑cadherin axis in the suppres‑
sion of cellular invasiveness downstream of PDK4 (Fig. 5J). 
Inhibitor experiments also indicated that CPT suppressed 
the β‑catenin/N‑cadherin axis via the mTOR pathway. As 
illustrated in Fig. 5J, CPT‑associated inhibition of PDK4 
leads to the suppression of mTOR. Downstream of mTOR, 
β‑catenin was suppressed, causing the downregulation of 
N‑cadherin expression, a master regulator of EMT in bladder 
cancer cells. 
In the present study, CPT was revealed to exert a dual 
function in β‑catenin phosphorylation. CPT (10 µM) 
enhanced β‑catenin phosphorylation at S33/S37/T41 and 
suppressed phosphorylation at S552 in human bladder cancer 
cells. Phosphorylation of β‑catenin at S33/S37/T41 has been 
shown to promote its ubiquitylation and proteasomal degrada‑
tion (35,36). The suppression of β‑catenin phosphorylation at 
S33/S37/T41 induced its cytoplasmic accumulation, and some 
of the free β‑catenin translocated to the nucleus, resulting 
in deregulated cell cycle progression (35,36). Conversely, 
β‑catenin phosphorylation at S552 is known to promote its tran‑
scriptional activity and cancer cell invasiveness (39). Therefore, 
CPT is considered to suppress the invasion of bladder cancer 
Figure 2. Alterations in cancer‑related protein expression following CPT 
treatment. (A) Western blot analysis of proteins that regulate epithelial‑mesen‑
chymal transition and stemness in T24 and J82 cells treated with CPT for 
48 h. α‑tubulin was used as the internal control. (B) Subcellular localization 
of β‑catenin and phosphorylated β‑catenin (S552) in T24 cells treated with 
CPT for 48 h. Fractionated cytosolic and nuclear proteins were analyzed by 
western blotting using α‑tubulin and lamin A/C antibodies, respectively. 
(C) Western blot analysis of MEK/Erk, Akt, and mTOR pathway proteins 
in the T24 and J82 cells treated with CPT for 48 h. α‑tubulin was used as 
the internal control. CPT, cryptotanshinone; p‑, phosphorylated; EpCAM, 
epithelial cell adhesion molecule; 4EBP1, eukaryotic translation initiation 
factor 4E‑binding protein 1.
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cells by both promoting the ubiquitylation and degradation of 
β‑catenin, as well as suppressing its transcriptional activity. In 
the present study, 20 µM CPT markedly suppressed β‑catenin 
phosphorylation at S33/S37/T41 in bladder cancer cells, which 
appeared to be attributed to the decrease in total β‑catenin 
expression due to its ubiquitylation and degradation. The 
enhanced nuclear accumulation of β‑catenin has been observed 
in bladder cancer tissues, resulting in enhanced transcription 
of genes such as Snail and Twist (40). In the present study, 
β‑catenin nuclear localization was decreased by CPT treat‑
ment in bladder cancer cells, which suggests that the alteration 
in β‑catenin function is closely associated with CPT‑induced 
suppression of tumor growth and cellular invasiveness.
CPT also suppressed the expression of cancer stem cell 
markers, CD44 and EpCAM, in bladder cancer cells, reflecting 
the inhibitory effect of CPT on cancer stem cell proliferation. 
In fact, CPT inhibited the representative phenotype of cancer 
stem cells and 3D‑spheroid formation in bladder cancer cells. 
Furthermore, CPT significantly suppressed in vivo tumor 
growth and peritoneal dissemination in an orthotopic mouse 
model of SUIT‑2 pancreatic cancer. CD44 is a cancer stem 
cell marker and a major surface receptor for hyaluronate, 
that has been shown to play a role in intracellular adhesion, 
cell‑matrix adhesion, migration and tumor cell invasiveness 
and metastasis (41‑43). Van Grevenstein et al (44) suggested 
that interference with CD44 may decrease the incidence of 
Figure 3. Effects of PDK4 and β‑catenin siRNA‑knockdown in T24 cells. Cells were treated with siRNA for 24 h, followed by nonadherent culture for 48 h, 
or 3D‑spheroid formation for 72 h. (A) Western blot analysis for PDK4 and PDH proteins in T24 cells treated with Ci (siRNA control) and PDK4 siRNAs. 
α‑tubulin was used as the internal control. (B) Effects of PDK4‑ and β‑catenin‑knockdown on the viability in T24 cells. Bars indicate the mean ± SD. Adenosine 
triphosphate content was assessed using the CellTiter‑Glo® 3D assay. **P<0.001 compared with Ci control using Tukey's test. (C) Effects of siRNA for PDK4 and 
β‑catenin on the invasiveness in T24 cells. Each sample was assayed in triplicate, and the bars represent the mean ± SD. **P<0.001 using Turkey's test compared 
with Ci control cells. (D and E) Western blot analysis for epithelial‑mesenchymal transition, MEK, Akt, and mTOR pathway proteins in T24 cells treated with Ci, 
PDK4 and β‑catenin siRNAs, respectively. α‑tubulin was used as the internal control. CPT, cryptotanshinone; PDH, pyruvate dehydrogenase; PDK4, pyruvate 
dehydrogenase kinase 4; p‑, phosphorylated; 3D, three‑dimensional; Ci, siRNA control; 4EBP1, eukaryotic translation initiation factor 4E‑binding protein 1.
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peritoneal tumor recurrence after curative resection of pancre‑
atic cancer. In bladder cancer, CD44, Oct4 and EpCAM have 
been shown to be highly expressed in, and associated with 
the progression of, bladder cancer (45,46). The present study 
also investigated the expression of Oct4 and retinal dehydro‑
genase 1. However, the expression of these proteins was low 
and not affected by CPT treatment in T24 and J82 cells (data 
not shown). 
The mTOR signaling pathway has been reported to be 
a master regulator for the maintenance of cancer cell stem‑
ness (45,47,48). Previous research has demonstrated that cancer 
stem cells undergo metabolic alterations, including high glyco‑
lytic activity and low mitochondrial respiration (49). The results 
of the present study also suggest that the metabolic alterations 
caused by inhibiting PDK4 activity can suppress the stemness 
of bladder and pancreatic cancer cells. PDK4‑knockdonwn 
analysis indicated that the inactivation of PDK4 contributed 
to decreased CD44 expression, although its suppression was 
independent of that of the mTOR/β‑catenin/N‑cadherin axis. 
N‑cadherin has been shown to play a central role in the induc‑
tion of EMT, which primarily contributes to the invasion and 
metastasis of malignant cancers (50). The dual suppression of 
CPT‑induced EMT and cancer cell stemness via PDK4 inacti‑
vation may present a novel therapeutic approach for intractable 
malignant cancers.
The results of the present study also revealed that mTOR 
was a critical downstream target molecule of PDK4 for 
suppressing cellular invasiveness by CPT via β‑catenin and 
N‑cadherin. The mTOR (mTORC1) pathway is a central 
signaling pathway that controls metabolic processes (51,52). 
Studies using specific inhibitors have elucidated the role of 
mTOR in the control of cell proliferation and metabolism (53). 
The Wnt/β‑catenin and Akt/mTOR pathways have been shown 
to be critically involved in colorectal cancer development (54) 
and are primarily regulated by feedback mechanisms. They 
are connected at multiple levels involving common upstream 
and downstream effectors. In the present study, mTOR acted 
upstream of β‑catenin to suppress EMT and invasiveness 
following CPT administration. mTOR orchestrates meta‑
bolic reprogramming by regulating nutrient uptake and flux. 
Although various clinical trials have used rapamycin and its 
analogs, their therapeutic effects are limited by modest anti‑
tumor activity and increased toxicity. The results of the present 
study demonstrated that CPT was able to suppress the mTOR 
pathway, as well as other signaling cascades, at low concentra‑
tions. CPT also suppressed metastasis and tumor growth in 
an in vivo mouse orthotopic model without causing severe 
side effects. We also hypothesize that CPT and conventional 
mTOR inhibitors may synergistically suppress tumor growth, 
invasion and metastasis at low concentrations by altering 
cellular metabolism; however, the detailed mechanism by 
which PDK4 inactivation suppresses mTOR activity requires 
further investigation. Although our previous study investigated 
the inhibitory effect of CPT on PDK4 by in vitro, whether CPT 
can directly bind to and inhibit PDK4 in vivo remains to be 
elucidated.
Our previous study reported that CPT significantly 
inhibited the 3D‑spheroid formation of pancreatic cancer 
cells at micromolar‑order concentrations, without inducing 
apoptosis (15). In the current study, the induction of apoptosis 
was detected at low levels in T24 and J82 bladder cancer cells. 
Liu et al (55) reported that CPT promoted the apoptosis of 
bladder cancer cells in a dose‑dependent manner. In their report, 
apoptosis was potently induced with 40‑80 µM CPT, a higher 
concentration than that used in the present study (10‑20 µM), 
suggesting that a difference in CPT concentration might 
contribute to the induction of apoptosis in bladder cancer 
cells. Furthermore, a low concentration of CPT was sufficient 
enough to suppress invasion and tumor growth, suggesting its 
potential as a clinical cancer therapy without considerable side 
effects. Cisplatin‑based chemotherapy remains the standard 
first‑line treatment for advanced bladder cancer (24), though 
patient outcomes remain insufficient. Thus, novel strategies 
for the treatment of advanced bladder cancer are required. 
The PDH‑PDK axis has been considered a crucial therapeutic 
target in cancer (7,10,11) because PDK4 plays a pivotal role 
in the altered metabolism of malignant cancers (7,9). This 
Figure 4. Effects of mTOR, Akt and Erk inhibitors in T24 cells. Western 
blot analysis following treatment with (A) the mTOR inhibitor, temsi‑
rolimus, (B) the Akt inhibitor [1L‑6‑hydroxymethyl‑chiro‑inositol 
2‑((R)‑2‑O‑methyl‑3‑O‑octadecylcarbonate)], and (C) the Erk inhibitor 
PD98059. (C) T24 cells were treated with each reagent at 40 µM for 48 h. 
α‑tubulin was used as the internal control. 4EBP1, eukaryotic translation 
initiation factor 4E‑binding protein 1.
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therapeutic strategy warrants small molecules that effectively 
inhibit PDK4 activity without exhibiting toxicity. However, 
the current findings on CPT will contribute to targeting 
or suppressing the invasion and metastasis of intractable 
malignant cancers.
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